Trust in telemedicine from IBD outpatients during the COVID-19 pandemic
- PMID: 33187917
- PMCID: PMC7644233
- DOI: 10.1016/j.dld.2020.10.035
Trust in telemedicine from IBD outpatients during the COVID-19 pandemic
Conflict of interest statement
Declaration of Competing Interest AC received lecturer fees from Takeda, a sponsorship from Bracco, FC served as a consultant to: Mundipharma, Abbvie, MSD, Takeda, Janssen, Roche, Celgene. FC received lecturer fees from Abbvie, Ferring, Takeda, Allergy Therapeutics, Janssen and unrestricted research grants from Giuliani, Sofar, MSD, Takeda, Abbvie. MV served as consultant to: Abbvie, MSD, Takeda, Janssen-Cilag, Celgene. He received lecturer fees from Abbvie, Ferring, Takeda, MSD, Janssen-Cilag, Zambon. All the remaining authors declare no conflict of interest.
Figures
References
-
- Dorsey E.R., Topol E.J. State of telehealth. N Engl J Med. 2016;375(2):154–161. - PubMed
-
- Daschle T., Dorsey E.R. The return of the house call. Ann Intern Med. 2015;162(8):587–588. - PubMed
-
- Toruner M., Loftus E.V., Jr, Harmsen W.S. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929–936. - PubMed
-
- Bezzio C., Saibeni S., Variola A. Italian group for the study of inflammatory bowel disease (IG-IBD). Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020;69(7):1213–1217. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
